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Capsule Summary 37 
Dexamethasone induces the production of DHA-derived specialized proresolving lipids 38 
and the resolution of allergic airway inflammation. This adds glucocorticosteroids to 39 
the short list of drugs that are known to possess direct pro-resolving functions. 40 
 41 
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To the Editor 42 
Resolution of inflammation has long been considered to be a passive process 43 
that ensues in an inflammatory response following the dilution of pro-inflammatory 44 
cues. However, this paradigm is shifting as it is becoming increasingly evident that 45 
resolution is an active reaction that employs a complex molecular machinery that 46 
orderly terminates inflammation. Among the multiple mechanisms involved, 47 
specialized proresolving lipid mediators (SPMs) such as resolvins, protectins and 48 
lipoxins have taken center stage1. These are derived from 3 and 6 polyunsaturated 49 
fatty acids through complex intra- and trans-cellular biosynthetic pathways, and 50 
promote resolution of inflammation by their manifold and concerted functions 51 
inhibiting leukocyte trafficking, dampening pro-inflammatory signaling, inducing 52 
apoptosis, and promoting anti-inflammatory M2-like macrophage phenotypes 53 
efferocytosis and tissue restitution1. 54 
Impaired induction of SPMs has been associated with defective resolution of 55 
inflammation and chronic diseases including asthma. Thus, reduced Lipoxin A4 (LXA4) 56 
levels have been detected in blood, bronchoalveolar lavage fluid (BAL), sputum and 57 
exhaled breath condensates of severe asthma patients, correlating with disease 58 
severity2-4. Moreover, impaired protectin D1 (PD1) production has been described in 59 
asthma patients compared to healthy individuals5,6. These observations are 60 
functionally relevant since administration of synthetic forms of SPMs in animal models 61 
of asthma have been notably effective in resolving inflammation7. Still, little is known 62 
about the effect of known drugs in the production of proresolving lipids, hampering 63 
the exploitation of this emerging new knowledge for therapy. 64 
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Here, we have investigated the role of dexamethasone (DXM), a prototype 65 
prototypical glucocorticosteroid, in the generation of SPMs and the resolution of 66 
inflammation. We employed an established model of allergic airway disease based on 67 
ovalbumin (OVA) sensitization and challenge (Fig E1, A) which triggers a Th2-driven 68 
inflammatory response in the airways peaking at day 1 post-challenge and gradually 69 
resolving thereafter (Fig E1, B-D)7. This is accompanied by the production of DHA-70 
derived protectins such as PD1 and PDX, and their intermediate metabolite 17-HDHA, 71 
in the lung which starts at day 1 and peaks at day 4 post-challenge (Fig E1, E), in line 72 
with their proresolving activity. By contrast, vehicle control (PBS) challenge does not 73 
trigger any SPMs (Fig E1, E). Prostaglandins PGD2 and PGE2 which are required for the 74 
activation of SPM pathways8 are also induced, while the EPA-derived metabolite  RvE1 75 
is not detectable (data not shown). The induction of SPMs is topical as none of these 76 
mediators is up-regulated in serum (Fig E2). 77 
 Using this setting, we administered DXM therapeutically, at days 1, 2 and 3 78 
post-challenge, and assessed its effects (Fig 1, A). Surprisingly, we observed rapid and 79 
robust activation of the DHA•17-HDHA pathway within 6h of DXM administration (day 80 
1 post-challenge), resulting in over 103-fold higher concentrations of PD1 and PDX 81 
compared to naïve animals whereas vehicle (PBS)-treated controls exhibited no 82 
difference (Fig 1, B). This may even be an underestimation as in naïve and most 83 
vehicle-control treated animals PD1 and PDX are completely undetectable but an 84 
arbitrary value of half the limit of quantification was still used for fold calculations. 85 
RvE1 and LXA4 were not detected while PGD2 and PGE2, although present, were not 86 
differentially altered (data not shown). This early boost in SPM production was not 87 
anymore detectable 24h or 72h after DXM administration (day 2 or 4 post-challenge), 88 
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as levels in vehicle-control treated animals were also increased, while at 144h (day 7 89 
post-challenge) higher, yet not significant, levels of PD1 and PDX were observed in the 90 
control group (Fig 1, B). These findings demonstrate that DXM acutely induces the 91 
mobilization of the DHA•17-HDHA•PD1/PDX pathway during allergic airway disease 92 
in mice.  93 
 We then examined whether the ability of DXM to up-regulate PD1 and PDX 94 
could also modulate resolution of allergic airway disease. DXM was unable to generate 95 
a notable anti-inflammatory or proresolving effect within 6h of treatment, a very short 96 
time interval (Fig 1, C-D). However, at 24h (day 2 post-challenge) and onwards DXM 97 
reduced total leukocyte and eosinophil numbers in the BAL more rapidly than vehicle 98 
control, and decreased OVA-specific IL-5 and IL-13 levels in mediastinal lymph nodes 99 
(MLNs). Accordingly, DXM shortened the resolution interval (Ri), the time interval 100 
from the peak of inflammation at day 1 post-challenge to the 50% reduction point, by 101 
2 days, a very significant effect for this model (Fig 1, E-F). To confirm that DXM 102 
accelerates the resolution of inflammation through the induction of DHA-derived 103 
SPMs, rather than other effects on the immune system, we employed 12,15-104 
lipoxygenase deficient (Alox15-/-) mice which cannot metabolize DHA to downstream 105 
bioactive mediators such as protectins (Fig 2, A-B).  Abrogation of PD1 and PDX 106 
generation completely reversed DXM-mediated resolution of allergic airway 107 
inflammation including total leukocyte and eosinophil infiltration in the BAL, and Th2 108 
cytokine production in MLNs (Fig 2, C-D and E3, A-B). Although this does not exclude 109 
the involvement of other bioactive lipids requiring 12,15-lipoxygenase for their 110 
generation, the potent proresolving activity of syntheric PD1 administration in similar 111 
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settings5, 7 indicates that at least PD1 and its functionally similar isomer PDX are 112 
principally involved.  113 
In conclusion, our study describes a novel function of DXM, a prototype 114 
prototypical glucocorticosteroid, in the activation of SPM networks. It reveals that 115 
DXM enhances the catabolism metabolism of DHA to its bioactive derivatives PD1 and 116 
PDX. This effect is rapid, inducing at 103-fold higher levels than background vehicle 117 
within 6h of treatment, providing an early boost to the process of resolution, markedly 118 
reducing both the duration and magnitude of inflammation. This effect is also 119 
transient as no differences between DXM and vehicle-treated animals were observed 120 
later on, possibly reflecting the induction of counter-regulatory pathways suppressing 121 
SPM networks, and lack of need for additional SPMs in an effectively resolving 122 
situation. Notably, the effect of DXM is specific for the D-series SPMs since there was 123 
no observed mobilization of other proresolving pathways such as lipoxin A4 or E-series 124 
resolvins nor PGD2 and PGE2.  125 
At present, very few pharmaceutical substances have a documented ability to 126 
activate SPM networks. Aspirin and statins provoke conformational changes on 127 
cyclooxygenases altering their enzymatic activity and leading to the production of 128 
epimeric forms of lipoxins, resolvins and protectins, depending on the substrate9. 129 
Resiquimod, a TLR7/8 agonist, induces in turn DHA-derived SPMs in human 130 
macrophages and experimental settings of airway disease7.  Synthetic forms of SPMs 131 
such as RvE1 and LXA4 are also being explored although their short half-life and 132 
chemical stability constitute major hurdles towards their clinical application. Our 133 
study therefore adds DXM as a new agonist of resolution, expanding the short list of 134 
clinically used drugs that are able to actively induce SPM pathways. It also provides 135 
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novel insight into the mechanism of action of DXM, a well-known and widely-used 136 
drug, with important implications for glucocorticosteroid use in the clinic.  137 
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SPMs = specialized pro-resolving lipid mediators, DHA = docosahexaenoic acid, PUFAs 202 
= polyunsaturated fatty acids, PD1 = protectin D1, PDX = protectin DX, LM = lipid 203 
mediators, LXA4 = lipoxin A4, LTB4 = leukotriene B4, BAL = bronchoalveolar lavage 204 
fluid, LOX = lipoxygenases, COX = cyclooxygenases, NSAIDs = non-steroidal anti-205 
inflammatory drugs, PGs = prostaglandins, LTs = leukotrienes, GCs = 206 
glucocorticosteroids, GR = glucocorticoid receptor, DXM = dexamethasone, OVA = 207 
ovalbumin, EXC4 = eoxin C4, RvE1 = resolvin E1, RvD1 = resolvin D1, 17-HDHA = 17-208 
hydroxy-docosahexaenoic acid, 7-HDHA = 7-hydroxy-docosahexaenoic acid, EPA = 209 
eicosapentaenoic acid, LC-MS/MS = liquid chromatography tandem mass 210 
spectrometry, Ri = resolution interval, IL = interleukin 211 
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Figure Legends  212 
Figure 1. Effect of DXM on the biosynthesis of DHA-derived proresolving lipid 213 
mediators and the resolution of allergic airway inflammation. (A) Schematic of the 214 
experimental protocol. DXM treatment is depicted in red. (B) Tissue lipidomic profiling 215 
over a time-course of 7 days post-challenge showing early activation of the DHA-17-216 
HDHA-PD1/PDX pathway triggered by DXM. Data are expressed as fold induction 217 
relative to naïve non-inflamed mice. (C) Total leukocyte, eosinophil and lymphocyte 218 
numbers in BAL. (D) TH2 cytokine responses in mediastinal lymph nodes. (E) Resolution 219 
curves for total leukocyte and eosinophil numbers in BAL. (F) Calculated resolution 220 
intervals (Ri) based on total leukocyte and eosinophil resolution curves. Data 221 
represent mean±SEM of n=9-23 mice/group pooled from at least three independent 222 
experiments. In fold calculations half the limit of quantification (LOQ) was used for 223 
samples beyond detection. ***P<0.001, **P<0.01 and *P<0.05 compared to PBS-224 
treated controls. 225 
 226 
Figure 2. Dependence of DXM pro-resolving capacity on the activation of the DHA-17-227 
HDHA-PD1/PDX pathway. (A) Schematic of the experimental protocol employing wild 228 
type (WT) and Alox15-deficient (Alox15-/-) mice depicted in red. Data are expressed as 229 
fold induction relative to naïve WT mice. (B) Tissue lipidomics analysis in of non-230 
treated Alox15-/- mice compared to WT mice. (C) Effect of DXM administration on total 231 
leukocyte, eosinophil and lymphocyte numbers in BAL at day 4 post-challenge. (D) 232 
Effect of DXM administration on TH2 cell responses at day 4 post-challenge. Data 233 
represent mean±SEM of n=6-23 mice/group pooled from at least three independent 234 
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experiments. BLQ: Below the Limit of Quantification. ***P<0.001, **P<0.01 and 235 
*P<0.05 compared to WT mice. 236 
